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INTRODUCTION
Graft-versus-host disease (GVHD) remains the leading cause 
of morbidity, non-relapse mortality and treatment failure 
post allogeneic haematopoietic stem cell transplantation 
(allo-HSCT). It occurs under acute (aGVHD) and chronic 
(cGVHD) forms. Around 50% of all allo-HSCT patients will 
develop some type or degree of GVHD.1-3 GVHD is respon-
sible for one third of the transplant-related deaths but is also 
the cause of severe morbidities with high impact on auto- 
nomy, possibility of self-supporting, chance to resume a 
professional life and globally on the quality of life of the 
patient.4,5 GVHD is responsible for repeated long hospita- 
lisations for infection treatment and organ dysfunctions.6 
So far, steroids and increase or restart of the immunosup-
pressive treatment that was given for GVHD prevention 
(cyclosporine, tacrolimus or rapamycin) when it was already 
tapered or stopped are the widely used first line treatment. 
Complete response (CR) to first line treatment is reported 
to occur in 25-40% of patients and clinically relevant impro-
vement is achieved in 40-50%.7 However, the likelihood of 
response decreases with increasing severity of the disease.8,9 
Around 40% of patients become steroid-resistant or fail to 
respond at a safe dose. Patients who fail to respond to the 
initial therapy have a dismal prognosis and no standard 
treatment is well established for them to date. A number 
of phase II trials of secondary regimens for patients with 
steroid-refractory GVHD have been published, and most 
of them reported a success rate ranging from 25-60%.10,11 
Second line immunosuppressive treatments are associated 
with a high mortality from opportunistic infections, malig-
nant relapse, secondary neoplasms and other serious com-
plications. Clinical manifestations of cGVHD can persist for 
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prolonged periods of time, and patients require a median of 
two to three years of therapy. As a result of their chronic 
immune suppression, about 40% of all patients with cGVHD 
will die within five years of infection or develop recurrent 
malignancy.12,13
Treatments that modulate the immune system rather than 
directly suppressing its function, although not dampening 
a potential graft-versus-malignancy effect, would therefore 
be highly desirable, and extracorporeal photopheresis (ECP) 
appeared as being a good candidate to fill in these criteria.14-16 
ECP has indeed emerged as a safe and efficacious non- 
pharmacologic immunomodulatory approach for the mana- 
gement of patients resistant to the first line treatment of 
GVHD. Since the Food and Drug Administration (FDA)’s 
first approval in 1988, ECP is being increasingly used 
around the world.17 Despite its frequent usage, the optimal 
role of ECP in the setting of GVHD still needs to be defined. 
TECHNICAL ASPECTS OF EXTRACORPOREAL 
PHOTOPHERESIS
Each session of ECP is an invasive procedure. Patients should 
have adequate haemoglobin levels (>10 g/dl) and platelets 
count (>20 x 109/L) as for other apheresis treatments. Patients 
exhibiting idiosyncratic or hypersensitivity reactions to me-
thoxsalen or other psoralen compounds and patients posses-
sing a specific history of a light-sensitive disease state are 
contraindicated for such therapies. Diseases associated with 
photosensitivity include lupus erythematosus, porphyria 
cutanea tarda, erythropoietic protoporphyria, variegate por- 
phyria, xeroderma pigmentosum, and albinism. There are 
no adequate studies of methoxsalen in pregnant women, we 
should therefore consider that it may cause foetal harm 
when given to a pregnant woman. Psoralen is also contrain-
dicated in patients with aphakia because of the significantly 
increased risk of retinal damage due to the absence of 
lenses. Patients should not start photopheresis treatment if 
they have any contraindications to the apheresis procedure. 
There are two methods to perform ECP. The two methods 
differ in the devices used for the collection of leucocytes as 
well as for UVA irradiation. They can be classified into 
‘on-line’ and ‘off-line’ methods based on the type of devices 
used. The ECP procedure consists of four steps: (a) collection 
of peripheral blood mononuclear cells by apheresis, (b) ex vivo 
incubation of mononuclear cells with 8-methoxypsoralen 
(8-MOP; a photoactivating drug), (c) irradiation of cells with 
UVA, (d) reinfusion of the treated cells into the patient.23,24
The on-line method allows for a one step procedure, during 
which the patient remains constantly connected to the 
system, can be performed on the Therakos CELLEX Photo- 
pheresis System (Therakos–Mallinckrodt Pharmaceuticals) 




and is based on an integrated, automated closed loop using 
a single device integrating the photoactivation chamber. 
At least 1 x 109/L cells in the peripheral blood are recom-
mended before initiating ECP therapy.25,26 The instrument 
separates and collects the lymphomonocyte fraction through 
centrifugal force while the other components are returned 
back into the patient. The buffy coat fraction remains in the 
system where it is treated with 8-MOP and subsequently 
exposed to the UVA.27 Finally, treated leucocytes are rein- 
fused back into the patients. The Therakos CELLEX instru-
ment can operate in both discontinuous and continuous 
modes. The continuous, ‘double-needle mode’ requires sepa-
rate collection and return vascular sites. If the procedure 
starts in the double-needle mode and one of the access sites 
is lost, the mode can be converted to single needle for the 
completion of the therapy.28 The closed system approach 
reduces the risk for bacterial contamination. After each ses-
sion, the patient should be prescribed high SPF sunscreen 
(15 or above) and UVA sunglasses (for 24h after each session) 
to avoid the adverse effect of 8-MOP used. Macopharma 
has proposed an alternative off-line strategy to perform ECP. 
The Macopharma (Theraflex ECP) approach is based on a 
standard mononuclear cell apheresis, injection of the 8-MOP 
in the apheresis bag, UVA exposure of the bag and reinfusion 
of the cells into the patients. In off-line methods, new aphe-
resis devices offer a higher collection efficiency of lympho- 
cytes resulting in greater cellular harvest. However, there are 
no data showing a correlation between a greater number of 
cells processed and the therapeutic response. A major disad-
vantage of the off-line method is the need of a cell therapy 
facility to treat the apheresis bag.  
ECP treatment is usually administered in two separate 
sessions over two consecutive days. Treatment can either be 
performed on an outpatient (with patients returning home 
between sessions) or inpatient basis (patients stay overnight 
with the first treatment in an afternoon and the second 
treatment on the following morning). It is possible that 
when a large number of cells are harvested and treated using 
the off-line system, one session per cycle could be enough. 
Several papers have reported on the safety profile of ECP of 
more than 500,000 ECP treatments performed worldwide 
since 1987. The incidence of reported adverse events is 
<0.003%.29 Adverse reactions can be related to leucapheresis 
such as reactions to volume shift in the extracorporeal circuit, 
citrate toxicity due to the anticoagulant used or bleeding 
from the cannula sites. Reaction related to exposure to 
psoralen can include increased urinary output, metallic 
taste and sparkly bits in the eyes. On reinfusion of the ECP 
products, some patients complain of mild fever, tiredness, 
headache, nausea and haematuria (due to reinfusion of red 
blood cells after exposure to 8-MOP).
EXTRACORPOREAL PHOTOPHERESIS’ 
MECHANISM OF ACTION
Although ECP has been in use for 30 years, its immuno- 
modulatory mechanism of action is not yet fully understood. 
FIGURE 2. The UVAR-XTS and CELLEX photopheresis closed systems.
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ECP exerts multiple effects on the immune system due to (a) 
changes induced in the mononuclear cells by the environ-
mental changes of harvested cells, (b) cellular changes due 
to treatment of cells by psoralen and exposure to UVA rays 
and, finally, (c) changes in the cytokine environment and 
immune cell function in the recipient following the reinfusion 
of the treated cells.
First, ECP induces apoptosis of activated lymphocytes 
within 24 to 48 hours of treatment, which results from inter-
calation of DNA when 8-MOP is activated by exposure to 
UV light.30 However, it is unlikely that the induction of apop-
tosis of treated lymphocytes represents the main mechanis-
tic action of ECP, as only 5-10% of circulating leucocytes are 
treated.17,31,32 Rather, phagocytosis of the treated apoptotic 
lymphocytes by antigen-presenting cells (APCs) and the 
induction of tolerogenic dendritic cells from treated mono-
cytes appear to hold a more pivotal role in the induction of 
allospecific tolerance.16,31,33,34 On reinfusion of irradiated 
cells, the cytokine network shifts with an increase in inhi-
bitory cytokines (interleukin-10, interleukin-4, transforming 
growth factor beta [TGF-β]) and a decrease in inflammatory 
cytokines (interleukin-12, interferon-α, tumour necrosis 
factor-α, interleukin-1) resulting in a shift from T-helper 
(Th)1 to Th2 response and an increase in antigen-specific 
circulating T-regulatory cells (Tregs). In vivo apoptosis of 
treated neutrophils could also modulate T-cell proliferation, 
induce indirect effects on APCs and lead to a decrease of 
inflammatory activity and tissue damage.16,35-37 Moreover, 
Rieber et al. demonstrated that ECP treatment in GVHD 
patients increases neutrophilic myeloid-derived suppressor 
cells, which modulate Th1 and Th17 responses.38 It is not 
known whether this is important for the clinical response to 
ECP. So far, no study has investigated whether B lympho- 
cytes play a role in ECP immunomodulation.16
However, the generation of Tregs and tolerogenic dendritic 
cells neither explains how ECP selectively targets pathogenic 
T cells without inducing systemic immunosuppression nor 
explains how it works in cutaneous T-cell lymphoma.14,28  How 
ECP could trigger both an anti-tumour immune response 
and immune tolerance remains indeed an open question. 
The pathologies treated by ECP are heterogeneous; however, 
they are all mediated by a (oligo)clonal T-cell population 
(tumoral T-cell clones in cutaneous T-cell lymphoma, allo- or 
auto-reactive oligoclonal T cells in GVHD and autoimmune 
diseases). Thus, these T cells share unique or a few T-cell 
receptors (TCR) representing pathogenic T-cell-specific anti-
gens that can be subsequently targeted by ECP-induced 
immune responses. Importantly, the presence of this patho-
genic T-cell population within the treated cells is critical for 
ECP efficacy.39 These critical data underlie the necessity of 
providing dying pathogenic T cells (containing specific anti-
gens) in order to obtain a therapeutic response, evoking 
an anti-(oligo)clonotypic immune response triggered by the 
repeated reinfusion of treated pathogenic T cells. ECP-indu-
ced immune cell death of pathogenic T cells could reconcile 
the apparently contradictory modes of action proposed so 
far.40,41 By promoting immune tolerance and simultaneously 
avoiding systemic immunosuppression, ECP could reduce 
GVHD and enable a reduction in other immunosuppression, 
allowing thymic recovery, restoration of normal T lympho-
poiesis and complete immunoreconstitution.31
VENOUS ACCESS
ECP procedures take several hours, and patients undergo 
these procedures for weeks or months. 
A recent international survey of ECP practice found that 
venous access issues were the number one reason given as a 
barrier to patients receiving ECP therapy. Peripheral access 
using venous needles (17-gauge inlet line and 17-/19-gauge 
return line) is most desirable to minimise any catheter-related 
infectious risks. In patients who have a long-term central 
venous access (CVC), this can be used for either inflow or 
outflow. A double-lumen CVC in subclavian or jugular can 
also be used (7-10 Fr for children and 12-14 Fr for adults to 
BOX 1. Key steps through which extracorporeal photopheresis is believed to reduce T-cell-mediated immune 
responses in patients with graft-versus-host disease. 
• apoptosis of white blood cells;
• phagocytosis of these apoptotic lymphocytes by antigen-presenting cells;
•  a switch in antigen-presenting cell activity in favour of anti-inflammatory cytokines and away from  
pro-inflammatory cytokines;
• production of antigen-specific immunosuppressive T-regulatory cells;




provide adequate flow rates, i.e., 2-5 mL/kg/min). These tem-
porary central venous catheters are nevertheless not recom-
mended for ECP due to the expected duration of therapy. 
A preliminarily check to confirm if the patient’s venous 
access is adequate is therefore essential before planning the 
start of treatment.42 
The repeated, prolonged venous access required for ECP 
often necessitates the use of an implantable vascular access 
device (IVAD), a tunnelled central venous catheter (TCVC) 
or a tunnelled central venous catheter with port (port-CVC). 
Although traditional subcutaneous port-CVCs have been 
used for ECP, these ports are not designed or approved for 
apheresis therapies. Under the best conditions, it is possible 
to achieve flow rates of 50-60 mL/min, which is acceptable 
for ECP but not optimal.43 In April 2017, the FDA approved 
the first subcutaneous port-CVC specifically designed for 
apheresis, the PowerFlow Implantable Apheresis IV Port 
(Bard Peripheral Vascular). It is designed with a titanium 
funnel rather than a septum. Unlike traditional port-CVCs 
that are accessed at 90°, the apheresis port-CVC is accessed 
at 30° relative to the skin surface. Blood flow rates at normal 
operating pressures (–100 mm Hg) range from 120 to 150 
mL/min depending on the gauge of the IV catheter port.44 
INDICATIONS OF EXTRACORPOREAL 
PHOTOPHERESIS IN 
GRAFT-VERSUS-HOST DISEASE 
PREVENTION OF GRAFT-VERSUS-HOST DISEASE
Considering the substantial rates of GVHD despite prophy-
laxis, novel prevention strategies are highly warranted. ECP, 
which is immunomodulating rather than immunosuppres- 
sive, could therefore be a very good candidate.45,46 Nowadays, 
there is no definitive evidence supporting the use of ECP for 
preventing GVHD occurrence, and it should not be done 
outside clinical trials.
TREATMENT OF ACUTE GRAFT-VERSUS-HOST 
DISEASE 
ECP is a valuable option in the treatment of either adults or 
children with steroid-refractory or steroid-dependent aGVHD. 
Besides anti-thymocyte globulin (ATG), ECP is the second 
most frequently reported second line treatment of patients 
with corticosteroid-refractory aGVHD.18  Some data suggest 
that early treatment shows better clinical results, but patients 
with a GVHD are usually qualified for ECP late in the course 
of the disease, after other therapeutic options are exhausted. 
At that time, because leukopenia is a typical feature in patients 
TABLE 1. Summary of clinical evidence on extracorporeal photopheresis as second line treatment in adult 
acute graft-versus-host disease.
Lead author Year N CR, % OR, %
Abu Dalle50 2014 54 Skin 84
GI 65
69









Jagasia58 2013 57 54
Skin stage I- II   70
        stage III-IV 57
Liver stage I-II    72
        stage III-IV 50
GI    stage I-II    77
        stage III-IV 54
66
Malagola59 2016 45 Grade II 97
Grade III 67
N/A
CR: complete response, OR: overall response, GI: gastrointestinal.
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treated for aGVHD, there is a decreased number of UVA 
irradiated cells, which in turn can limit the efficacy of ECP.47 
It seems therefore reasonable to start the ECP procedure in 
these patients earlier, when the white blood cell count is still 
abundant.48 Given its favourable adverse effect profile, ECP 
could be considered in all patients with aGVHD and cer-
tainly for treatment of aGVHD in patients for whom further 
immunosuppression is contraindicated due to viral reactiva-
tion or other infectious complications.49
The recommended ECP treatment schedule in aGVHD is 
not standardised between the different guidelines. In sum-
mary, it starts with two or three (intensified regimen) sessions 
the first to fourth week depending on severity and clinical 
response, then one ECP cycle (two consecutive ECP sessions) 
per week from weeks two to five and until week eight to 
twelve. At eight or twelve weeks: If a CR or partial response 
(PR) occurs, taper to one cycle every four weeks and stop 
after six months; if there is mixed response between different 
TABLE 2. Published survival data for adults with acute graft-versus-host disease.
Lead author Year N Years F/Up OR, %
Malik60 2014 595 1 49
Greinix48 2006 59 4 59*
Perfetti57 2008 23 Up to 81 months** 38
*complete responders only, **Retrospective review 1996-2006, F/Up: follow-up, OR: overall survival.
TABLE 3. Published response rates for extracorporeal photopheresis in the treatment of paediatric acute 
graft-versus-host disease: overall response and steroid tapering




Salvaneschi61 2001 9 78 43*
Messina62 2003 33 76 42* 36
Berger63 2007 15 Grade II: 100
Grade III: 75
Grade IV: 0 
Kanold64 2005 41 73
Kanold65 2007 12 83 30 33
Perseghin66 2007 10 70
Gonzalez-Vicent67 2008 8 100
Calore68 2008 15 100 67
Merlin69 2010 12 83
Gonzalez-Vicent70 2010 21 90
Perotti71 2010 50 68 16 at 30 days




GVHD targets, continue with one cycle/two weeks up to maxi-
mum six months and taper if a PR or CR is achieved; if steroid- 
dependent (SD) or progressive disease (PD): stop.15,29,48,50
From the data reported in the literature, summarised in 
Tables 1-4, responses were more common for patients with 
grade II than with grade III/IV aGVHD; CRs were seen in 
up to 100% of patients with grade II disease, whereas for 
patients with grade III/IV disease, complete remission was 
reached in around 40% of cases. Responses to ECP were 
more common for patients having skin involvement (66-84%) 
compared with gut (40-65%) or liver disease (27-61%). In 
general, ECP not only provides higher complete and partial 
response rates than alternative therapies, it also shows higher 
survival rates. Nevertheless, ECP superiority over other 
therapies cannot be firmly stated yet due to the lack of 
controlled randomised trials. Moving forward, randomised 
controlled studies are crucial to determine the optimal timing 
of initiation and treatment schedule for patients with aGVHD. 
Nowadays, ECP is recommended for the treatment of aGvHD 
by an increasing number of national and international guide-
lines and consensus papers.51-56
EXTRACORPOREAL PHOTOPHERESIS IN 
CHRONIC GRAFT-VERSUS-HOST DISEASE
As in aGVHD, no consensus has been reached regarding the 
optimal second line therapy in cGVHD patients. ECP has 
been used frequently in patients with steroid-refractory and 
steroid-dependent disease and is recommended in both adult 
and paediatric patients, either steroid-resistant or steroid- 
dependent, irrespective of disease extent and severity.52 
Documented improvements have also occurred in patients 
who have failed multiple therapies and suffered from GVHD 
for many months. Much clinical experience in cGVHD is 
based again on small case series and retrospective reviews. 
There are very few data available for the use of ECP as the 
first line therapy of cGVHD. Nevertheless, considering that 
the graft-versus-lymphoma effect seems to be not impaired 
by ECP, earlier use of ECP in cGVHD is recommended by 
some leading experts in the field, especially considering 
ECP inefficacy after irreversible tissue damage. Objective 
activity of ECP used as second line therapy and its positive 
impact on overall quality of life have been documented in all 
forms of cGVHD.72,73 
Due to the variety of ECP schedules applied, the impact of 
dose intensity and length of treatment cannot be assessed 
accurately based on the currently available literature.52 The 
most published treatment scheme for cGVHD is one cycle 
of ECP (two consecutive sessions) every two weeks up to 
a minimum of three months. At month three: if a CR or 
PR occurs, taper to one cycle every four weeks and stop after 
six months; if there is a mixed response, continue with one 
cycle/two weeks up to six months; if SD or PD: stop. Then, 
every three months revaluate the response; if there is a CR, 
taper to one cycle/four weeks for three months and stop if 
TABLE 4. Published survival data for children with acute graft-versus-host disease on extracorporeal photopheresis.
Lead author Year N Years F/Up OS, % PFS, % DFS, %
Salvaneschi61 2001 9 0.75 55
Messina62 2003 33 5 69*
Berger63 2007 15 N/A 100% Grade 
II; 30% Grade 
II-IV
Kanold65 2007 12 N/A 67
Calore68 2008 15 2 85 87
Gonzalez-Vicent70 2010 21 43
Perotti71 2010 50 5 46
Merlin69 2010 12 5 57
*Responders, F/Up: follow-up, OS: overall survival, PFS: progression free survival, DFS: disease free survival.
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TABLE 5. Published response rates for extracorporeal photopheresis in the treatment of chronic graft-versus-
host disease in adults.
Lead author Type Year No. studies N CR, % OR, %
McKenna88 Meta-analysis 2006 23 521 68























N/A Skin 40 vs 10 
Mucosa 53 vs 27
Liver 29 vs NA
Ocular 30 vs 7
Joint 22 vs 12
Seaton90 Prospective N/A Skin 53 Mucosa 50
Berger63 Single arm 
prospective
2007 N/A 10 30 ORR 40
Greinix77 Crossover 
prospective







Foss76 Single arm 
prospective










Dignan53 Retrospective 2012 N/A 82 7 ORR 79 Skin 100
Mucosa 91
Del Fante92 Retrospective 2012 N/A 102 16 ORR 81
Malagola59 Retrospective 2016 N/A 49 45 ORR 80
Pierelli85 Consensus 
statement






2008 23 521 Skin 68
Mucosa 63
Liver 63
Arun Alfred52 Consensus 
statement







*Included children and adults. No statistical difference in CR an OR between children and adults. Adults CR 26%;  
OR 78%. Paediatric CR 39%; OR 69%. ECP: extracorporeal photopheresis, OR: overall response, CR: complete 




there is a PR, continue with one cycle/four weeks to maximum 
response, taper and stop; if minor disease (MiD), SD or PD: 
stop.4,53,74-77
ECP has the highest specific response rate in cutaneous 
and oral mucosa cGVHD (50-85%) with improvement of 
both lichenoid and sclerodermic forms, followed by ocular 
(37-78%), liver (33-77%), lung (11-63%), musculoskeletal 
(18-94%) and gut (9-83%) cGVHD, with conflicting infor-
mation existing for bronchiolitis obliterans.78-81 In general, 
CRs are uncommon; as among patients with skin disease, 
CR has been reported in only 10-20%. 
The survival advantage of ECP in cGVHD has been well 
documented and is mainly attributed to steroid tapering or 
discontinuation. Patients benefit directly from steroid tape-
ring, but this effect cannot be achieved without offering them 
an alternative protection from debilitating complications of 
non-controlled cGVHD.82-84 In a study reported by Messina 
et al., the five-year overall survival was 58% for non-respon-
ders vs 96% for responders.62 There is also a suggestion that, 
in addition to clinical responses, ECP may also lead to 
an improvement in quality of life in cGvHD.73,85 The same 
statements as for cGVHD hold true for patients with overlap 
syndrome, although based on scant evidence.84 Available data 
from the literature are summarised in Tables 6-8. The stan-
dard use of ECP as a therapeutic option to treat steroid- 
refractory and -resistant cGvHD is also endorsed by national 
and international guidelines and consensus papers.51,52,54,85-89
APHERESIS CRYOPRESERVATION 
So far, few treatment centres that use the off-line method 
have frozen collected cells in aliquots to be thawed, treated 
and reinfused at a later time. This practice allows patients 
who travel long distances, lack appropriate intravenous 
access or cannot tolerate multiple apheresis procedures like 
children or because of their level of illness, to receive treat-
ment.69,95,96
More interestingly, Radwanski et al. reported that cryopre-
servation did not impair the apoptotic or anti-proliferative 
responses of ECP-treated lymphocytes from healthy volun-
teers, which could allow cryopreservation of treated cells.97 
While this method promises important logistical improve-
ments in patient treatment, additional studies are needed 
TABLE 6. Published response rates for extracorporeal photopheresis in the treatment of paediatric chronic 
graft-versus-host disease.
Lead author Year N OR, % CR, % Discontinuation 
of steroids, %
Tapering of steroids, 
%
Kanold64 2005 63 63
Perseghin66 2007 12 75
Salvaneschi61 2001 14 78 64 67
Halle94 2002 8 62 38
Messina62 2003 44 73 34 44 73*
Kanold  
(prospective)65
2007 15 73 27 27 Median tapering 30% 
after 10 sessions of 
ECP in responders





Perotti71 2010 23 22 26% @ 30 days
Gonzalez Vicent70 2010 6 90 50




to determine if these results from healthy subjects are repro-
ducible with patient lymphocytes and if the in vivo effective-
ness of the cryopreserved ECP-treated cells are maintained. 
We also need to improve our knowledge on the optimal cell 
dose to infuse per treatment. 
HOW SHOULD EXTRACORPOREAL 
PHOTOPHERESIS QUALITY BE MONITORED?
According to European guidelines for minimal cell manipu-
lation (Directive 2006/86/EC; Regulation 1394/2007/EC), 
off-line procedures should be performed in a Class A laminar- 
air-flow cabinet located in a Class D laboratory. During off- 
line procedures, cultures of the product for aerobic and anae-
robic bacteria and fungi should be done immediately before 
reinfusion into the patient. Sterility controls before the in-
troduction of 8-MOP are encouraged at least in two non-con-
secutive off-line procedures of each therapeutic course.
The number of lymphomononuclear cells treated with each 
ECP cycle is one of the major challenges in standardisation 
of this treatment modality. There is still no recommendation 
of a minimum number of cells to be processed per ECP 
session or an amount of blood volume to be processed for 
collection of cells.47 Collected cells from as low as 3.3 x 108 
(mini ECP) to up to 2.8 x 109 have been reported with ade-
quate clinical response. Some studies suggested that CD3+ 
T-cell dose harvested during the early treatment phase has 
an impact on subsequent clinical response.98 This ‘cell dose 
effect’ could nevertheless be the reflect of a minimum thres-
hold needed to trigger a therapeutic response rather than a 
true correlation between cell dose and therapeutic response, 
or it could be a surrogate marker of the presence of a large 
number of alloreactive lymphocyte clones in the patient 
blood. Other studies underline a role for myeloid and plas-
mocytoid dendritic cell precursors or immature peripheral 
blood circulating B cells at baseline. Finally, an increase in 
the Treg population, early during treatment course, has also 
been correlated to response.99,100 
The highest cell numbers are collected when using conven-
tional off-line apheresis compared to the on-line system. 
Most of the clinical data come from the on-line system and 
from two consecutive days of treatment per cycle.  It is, 
nevertheless, possible that one day of treatment per cycle 
instead of two could be sufficient if enough mononuclear 
cells can be collected in a single apheresis procedure. If 
TABLE 7. Published survival data for adults with chronic graft-versus-host disease. 
Lead author Year N Years F/Up OR, %
Messina62 2003 44 5 96
Couriel91 2006 71 5 41
* Responders only, F/Up: follow-up, OS: overall survival.
TABLE 8. Published survival data for children with chronic graft-versus-host disease.
Lead author Year N Years F/Up OR, %
Salvaneschi61 2001 14 3 79
Halle94 2002 8 3.6 75
Berger63 2007 10 2.6 40
Kanold65 2007 15 4.3 67
Perotti71 2010 23 5 83
Messina62 2003 44 5 77 (96 in responders)




this could be confirmed in a large trial, it could decrease 
the cost of ECP and make ECP more acceptable for patient 
quality of live.
As there is no consensus on cell number, critical cell sub- 
types and the central mechanism of action, there are no 
accepted standard, valid procedures to qualify the ECP 
product in a way that is predictable of its in vivo efficacy. 
Some teams have proposed a functional test to show the 
reduction in lymphocyte proliferative capacity on mitogen 
stimulation by carboxyfluorescein succinimidyl ester (CFSE) 
labelling.101,102 Two mitogens, PHA and CD3-CD28, could 
be used in parallel. Alternatively, measuring early and late 
8-MOP-induced apoptosis by simultaneous staining with 
annexin V-FITC and propidium iodide could also be used 
to confirm the technical efficacy of the procedure on mono- 
nuclear cells. Taverna et al. recommended assessing apopto-
sis at 24h with a goal of a minimum differential apoptosis 
rate of 15% between the ECP product and the control sample 
of the untreated apheresis product. Analysing apoptosis is 
less time-consuming (24h) than proliferation assays (3-5 days 
of culture), and easier too.103 Nevertheless, independently of 
the tests used, the question on how to define a threshold 
for considering an ECP procedure ‘unsuitable’ still warrants 
further investigations and, currently, stays an open question.
COST EFFECTIVENESS AND 
REIMBURSEMENT ISSUE
The cost of ECP could be covered by the money saved from 
the decrease of GVHD or GVHD treatments-related mor- 
bidities.18 It is clearly demonstrated that ECP reduces the 
rate and duration of hospitalisations associated with serious 
infections due to immunosuppressive treatments.19,20 Cost- 
effectiveness data from Spain and another analyses, conducted 
in Poland, showed that ECP is the most cost-effective alter-
native in the management of patients affected by cGVHD.21,22 
ECP is registered as standard therapy covered by social 
security in most of the European community countries. It is, 
nevertheless, highly paradoxical that ECP access is currently 
part of the new standards for the accreditation of the Joint 
Accreditation Committee for the International Society for 
Cellular Therapy and European Group for Blood and Marrow 
Transplantation ( JACIE), which is mandatory to be authorised 
to perform allogeneic transplantation in Belgium, because it 
is still not reimbursed by RIZIV/INAMI (Federal Institute 
for Health Insurance). The reimbursement issue drastically 
limits ECP access for patients in Belgium and creates a major 
difficulty for the Belgium transplant centres to comply with 
JACIE standards for accreditation. 
DISCUSSION
Although numerous studies on ECP, including those with 
open-label randomised designs, are available, the quality of 
evidence on ECP as a treatment option for GVHD is some-
what limited in part due to the absence of blind studies of 
ECP. Many of the studies quoted in the recommendations 
are also retrospective in nature. The predominant indication 
for ECP is the second line management of GVHD, and, as 
such, the delivery of an ECP service has been included in 
the Foundation for the Accreditation of Cellular Therapy 
(FACT)-JACIE quality standard recommendations for allo-
geneic hematopoietic stem cell transplant units. The standar-
disation of ECP treatment may be important in delivering 
KEY MESSAGES FOR CLINICAL PRACTICE
1 Around 50% of all allogeneic haematopoietic stem cell transplantation patients develop  
graft-versus-host disease.
2 Graft-versus-host disease is responsible for one third of transplant-related deaths.
3 Around 40% of patients become steroid-resistant or fail to respond at a safe dose.
4 Extracorporeal photopheresis has emerged as a safe and efficacious non-pharmacologic  
immunomodulatory approach for the management of the resistant graft-versus-host disease.
5 Extracorporeal photopheresis access is part of the new standards for JACIE accreditation but is,  
however, still not reimbursed by RIZIV/INAMI. The reimbursement issue drastically limits extracorporeal 
photopheresis access for patients in Belgium and creates a major difficulty for the Belgium transplant 
centres to comply with JACIE standards for accreditation.
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consistent therapy and produce reliable outcomes.52 Despite 
the number of proposed biomarkers, there is currently in-
sufficient evidence to recommend the routine use of biomar-
kers for the diagnosis, risk stratification or assessment of 
therapy response of GVHD. Studies, including biobanking 
of samples, attempting to identify biomarkers that could 
predict response and strict response criteria are being con-
ducted and will help to advance the field significantly.52 
Research will fill the current gaps in the knowledge on how 
exactly ECP influences the functional integration of various 
immune components with dissimilar activities. With emer-
ging GVHD therapies modulating the JAK-STAT and BTK 
pathways, the treatment options for GVHD patients are 
growing. Recently, ruxolitinib has shown very promising 
activity as rescue therapy for aGVHD and cGVHD refractory 
to standard therapy. Clinical trials comparing JAK-STAT 
and BTK inhibitors with ECP as second line for steroid- 
refractory GVHD are necessary to generate accurate treat-
ment algorythms.104 Clinical trials are essential to define the 
optimal use of ECP in the field of allogeneic HSCT; studies 
to evaluate its prophylactic use and as combination up-front 
therapy should be pursued.
CONCLUSION
Clinicians should consider ECP early on as a promising effec-
tive, safe and cost-effective therapeutic modality for those 
patients who do not have a fast and satisfactory response to 
corticosteroids for the treatment of GVHD irrespective of 
disease extent and severity. Multiple reports of treatments in 
both paediatric and adult patients with GVHD have been 
published, and the overall favourable profile compared with 
other available immunosuppressive therapies continues to 
make ECP appealing despite all of the unknowns.
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